Cerba And Taliaz to leverage Artificial Intelligence and Genetics Expertise to improve patient care management in depression
Saint Ouen l’Aumône (France) and Tel Aviv (Israel), October 20th, 2022 – Cerba, the foremost specialty clinical pathology reference, and Taliaz, an Israeli digital health company dedicated to improving mental health disorders, announced today a partnership to provide physicians with an AI-driven precision psychiatry solution that predicts treatment effectiveness in depression. By finding the right treatment from the very first prescription, the test helps physicians make the best therapeutic decision faster for their patients and can accelerate recovery of the 280 million people suffering from depression globally.
Today, 5% of the world’s adult population suffer from depression, one of the most common mental health disorders, according to the World Health Organization. The correct medical prescription of antidepressant compounds has become a critical issue in patient management as a lack of response or remission occurs in 20-30% of patients with a severe depressive episode. In France alone, 1 in 4 people struggle with mental health disorders, and 1 in 5 people suffer from depression.
To face this challenge, Cerba and Taliaz have joined forces to provide clinicians with a new clinical test that predicts the effectiveness of antidepressant treatments: PREDICTIX, developed by Taliaz, harnesses a biological test coupled with artificial intelligence to guide the management of depressed patients by presenting the medication with the best chance of therapeutic success the first time. Designed as a clinical decision support tool, the solution brings AI-driven precision psychiatry to the next level and is expected to improve care for millions of patients globally. It should be available for patients by January 2023 throughout the Cerba HealthCare clinical routine pathology network in France and abroad.
The PREDICTIX test uses AI to analyse multiple streams of patients’ data, including genetic, metabolic, demographic and clinical information. Doctors receive a personalized patient report that predicts and ranks the statistical efficacy, dosage and potential side effects of various antidepressant medications based on each patient’s pharmacogenetic makeup and health record. Clinical research demonstrated a response rate of 72.2 % and real-world data showed 90 % of patients experienced clinical improvement after 8 weeks according to the Clinical Global Impressions (CGI) Scale, a useful tool for clinicians and patients used in clinical practice.
Jérôme Sallette, Chief Scientific Officer at Cerba HealthCare comments: "With the introduction of PREDICTIX, we are entering a new age of precision medicine in psychiatry: empowering physicians to make the best therapeutic decision faster and reducing the burden of depression for patients and healthcare systems. Cerba is again at the forefront of innovation for enlightening diagnosis, improving patient health management and facilitating the right prescription at the right time for the right patient."
Dekel Taliaz, CEO and Co-founder of Taliaz, said, "We are delighted to sign this landmark agreement with Cerba HealthCare to help advance our mental health technology. Their scientific culture and extensive network will expand market entry for PREDICTIX towards global outreach. By leveraging the power of big data and AI in easy-to-use and time saving clinician tools, we are committed to bringing safe and efficient solutions to accelerate recovery and reduce suffering of patients with mental illness worldwide."
About Cerba HealthCare Cerba HealthCare, a leading player in medical diagnosis, aims to support the evolution of health systems towards more prevention. It draws on more than 50 years of expertise in clinical pathology to better assess the risk of diseases development, detect and diagnose diseases earlier and optimize the effectiveness of personalized medicine.
Every day, on 5 continents, the Group’s 15,000 employees sustain the transformation of medicine, driven by one deep conviction: to advance diagnosis is to advance health. Cerba HealthCare, enlightening health.
Additional information is available at www.cerbahealthcare.com
Laboratoire Cerba, at the origin of the Cerba HealthCare Group and world reference in specialized clinical pathology, performs complex analyses on behalf of other medical laboratories that cannot proceed with their own analyses due to the level of expertise, equipment and certification required.
For 50 years, Cerba’s medical and scientific teams have been assisting and advising healthcare professionals in the selection of the most relevant analyses and in the interpretation of the results to improve patient care. They are recognized by their peers in human genetics, onco-haematology, infectiology, endocrinology and immunology, pharmacotoxicology and metabolic diseases. With a panel of 1,300 exams covering 40 medical specialties, Cerba serves clinical pathology laboratories as well as private and public healthcare institutions in more than 50 countries.
For more information www.lab-cerba.com
Taliaz is revolutionizing mental health treatment and management with PREDICTIX. Combining science with AI, PREDICTIX translates complex genetic, demographic and clinical patient data into a time-saving assessment, prescribing and management support tool for healthcare providers. PREDICTIX improves treatment prescribing accuracy and can save 12% in mental health costs. PREDICTIX is CE-registered and currently available for commercial use in the EU (in France, Belgium and Switzerland), United States, United Kingdom, Australia and Israel. Learn more at https://www.predictix.ai/.